Med-Pak Technologies: A business development and technology licensing company.
Bridging the gap between innovative science and the marketplace
Partnership Opportunities

Patient Data Internet Platform Technology

This technology is a critical internet tool that significantly improves the ability to perform meaningful and successful disease management in humans.

This system provides the means to effectively manage the most costly medical conditions. It provides access to critical and non-critical data available to interested parties 24/7/365.  

This platform technology enables its end-users to perform streamlined, real time disease management that secures the best medical outcome for patients.

It will increase the revenue stream to primary physicians in the new paradigm of medicine in the United States entitled, “Medical Home”. Beginning in 2008 you will see a public record that grades the performance of doctors.  

It increases profits to risk organizations and healthcare insurance companies. 

All healthcare payers are attempting to use the concept of disease management as a pathway to reduce healthcare costs while improving the quality of life. Although healthcare providers desire to prevent or greatly reduce the effects of disease, none possess a successful disease management program.

This platform technology accomplishes the task through a proven specific medical data retrieval process that is timely, and that is always accessible and has the capability of measuring the final results. 

This platform technology offers the ability to review pertinent medical data in real time. This approach creates the best opportunity to suggest a best course of action to the patient and physician. The ability to monitor these changes, without dependency of claims data will be advantageous to any healthcare provider or disease management firm.

The technology captures data measured via quality control groups including the Healthcare Effectiveness Data and Information Set, Center of Disease Control, and the National Committee for Quality Assurance. The program also has the ability to sort the information in various forms at the pleasure of the end-user.

To learn more about this opportunity email us at: info @

top of the page

Infection Control - Water Filtration Device

This new proprietary device by Nephros’ is a new Dual Stage Ultrafilter, or DSU, a water filtration system that will be used initially in the hospital’s patient showers.

The Nephros DSU incorporates the company’s unique and proprietary dual stage filter architecture. The Nephros DSU is designed to remove a broad range of bacteria, viral agents and toxic substances, including salmonella, hepatitis, HIV, Ebola virus, ricin toxin, legionella, fungi and e-coli. The Nephros DSU removes these harmful substances more effectively than any other water filters currently available.

Water contamination is a critical and ongoing issue; the recent Katrina and Wilma storms drove that point home all too clearly. The Nephros DSU can offer a robust solution to a broad range of contaminated water problems. Hospitals are particularly stringent in their water quality requirements; transplant patients and other individuals whose immune systems are compromised can face a substantial infection risk in drinking or bathing with standard tap water that would generally not present a danger to individuals with normal immune function. With over 5,000 registered hospitals in the United States alone, the hospital shower and faucet market can offer a valuable opportunity as a first step in water filtration.

For distribution or licensing information email: info @

top of the page

Cholesterol Reducing Peptide

Our client has developed a proprietary peptide that binds LDL and modulates HDL/LDL levels.  This novel peptide has proven superior to currently available cholesterol treatments:

  • The peptide treatment may be administered through a transdermal patch, significantly reducing pill burden (the number of pills an individual must take daily).  Pill burden is the most commonly cited reason for patient non-adherence to treatment.
  • The peptide modulates HDL/LDL concentrations, thereby ensuring that healthy ratios are maintained.
  • The peptide is safe and presents no known adverse risk of side effect.  In contrast, Niacin, a treatment with comparable efficacy, is not well-tolerated, and statins, which are far less efficacious, present toxicity concerns such as liver disease and gastrointestinal disorder.
  • The peptide provides immediate results compared to the 2-4 weeks associated with statins.


top of the page

Alzheimer’s Disease Blood Test Diagnostic

This Alzheimer’s disease diagnostic represents a new and unique approach to AD diagnosis.  It empowers physicians to accurately assess the presence of AD and simultaneously opens new avenues of research for scientists to identify novel targets for treatment. 

The technology may also serve as a viable marker for other pathological conditions involving oxidative damage, such as Parkinson’s disease and Huntington’s disease1.  Therefore, it is ideally positioned to become a staple in the physical examination suite of analyses performed on all individuals above the age of 55 and those showing early symptoms of an oxidative damage-associated disease.


top of the page

Novel Breast Cancer Theranostic

This breast cancer theranostic has both immediate and long-term application. It allows a breast cancer patient’s personal physician to immediately assess tumor aggressiveness and the technology represents a new and unique approach to identify novel targets for cancer and its diagnosis. 

The technology also predicts the metastatic potential for other cancer types such as colon cancer, prostate cancer, brain tumors, and gonadal tumors1.

Therefore, it is ideally positioned to capture a significant fraction of the $10 billion breast disease management market as well as the markets associated with other cancers.


top of the page

HIV Novel Entry Inhibitor Therapeutic

Our client has developed SP-01a, an HIV treatment that has proven to be safe and highly effective.

In a Phase II clinical trial of HIV-positive patients who were currently adhering to HAART regimens, patients administered SP-01a experienced a statistically significant (meaning not likely by chance alone) decrease in viral load and improvement in Whalen Symptom Index symptoms (a scale that measures quality of life among HIV patients) despite presumably already having suppressed viral load counts.  When SP-01a was withdrawn from each patient’s regimen, their viral load counts returned to baseline despite their continued adherence to triple-HAART concomitant therapy. 

In addition to the favorable results obtained in viral load reduction and quality of life, the patients experienced no adverse side effects that could definitively be associated with SP-01. Moreover, HIV does not develop resistance to SP-01a.


top of the page

Pharmacological Animal Model for Alzheimer’s Disease

Our client has developed a proprietary compound that when injected in rats, produces full-blown AD pathology, including memory-loss, beta-amyloid plaque deposition and neurofribillary tangles, within four weeks.

Moreover, these symptoms persisted after nine months, proving the sustainability of the induced condition.  As a result, they were able to create an animal rat model on which to test the efficacy and safety of potential treatments for AD. 

The model has several distinct advantages.  First, healthy rats are used because their neuronal development and function most closely parallels that of humans.  Second, AD is induced by a non-genotypic source as is the case in more than 95% of human AD cases.  Therefore, the model parallels human AD pathology.  Third, rat subjects demonstrate AD in an extremely short period of time (within four weeks).  Therefore, researchers need not suffer the delays formerly associated with transgenic mice (6 to 18 months).  Fourth, the model is much less expensive than transgenic mouse models.  Finally, the models are conducive to therapeutic and vaccine research.


top of the page

Novel Compound for Alzheimer’s disease

Our client is in the midst preparing its pre clinical data which is being readied to apply for Investigational New Drug (IND) application with the FDA.

They are extremely excited regarding the development of this and other compounds. Their research scientists have determined that excessive accumulation in the brain of the beta-amyloid peptide, due either to overproduction and/or decreased clearance and the formation of senile plaques, is one of the hallmarks of Alzheimer disease.

This compound was identified based on its ability to protect neurons against beta-amyloid-induced toxicity. The compound was shown to bind to beta-amyloid peptide, prevent its oligomerization and entry into neurons, protect neuronal mitochondria from beta-amyloid-induced damage, and maintain neuronal cell energy levels. The preclinical data is suggesting that this compound as a new unique approach for Alzheimer's disease therapy.

Detailed studies on the mechanism of action of the compound, in rodent and human neurons, have been performed and the toxicity of the compound in "in-vitro" studies has been studied. Samaritan has performed the majority of the preclinical studies required to apply to the FDA for an IND and is currently performing toxicology studies.


top of the page

Stem Cell Drug Opportunities and Development

This client is presently fast tracking its research and development of its neuronal stem cell therapy drugs that can induce dormant brain neuronal stem cells to differentiate rapidly into adult neuron cells as a novel treatment for Alzheimer's disease and other neurodegenerative disorders. Repairing brain damage by replacing the lost neurons and restoring neuronal function is certainly the most ambitious and exciting challenge physicians and scientists are currently facing. In that aspect, the concept of stem cell therapy is extremely promising. Hence, the access to the differentiation of stem cells into neurons may serve as a database of specialized cells for regenerative medicine as a treatment for neurodegenerative diseases and brain stroke.

As a result of screening a database/collection of naturally occurring compounds the client identified compounds that were efficacious in inducing in-vitro and in rats' in vivo neural stem cell differentiation and neurogenesis. Further in vivo studies in animal models of neurodegenerative disease are in progress in order to validate the use of these compounds in regenerating the neuronal network from pre-existing stem cells in the adult.


top of the page

Advancements in ESRD Therapy

Our client has developed Mid-Dilution Hemodiafiltration, a unique and proprietary fluid management system offering optimized removal of renal toxins across the molecular spectrum. In concert with this technology, Nephros has developed a cost-effective online substitution fluid system that delivers ultra-pure substitution fluid in real-time. This effectively eliminates cost issues associated with earlier diafiltration systems.

Mid-Dilution Hemodiafiltration technology offers substantial improvements in efficacy within a cost structure similar to today's high flux dialysis.

Mid-dilution hemodiafiltration provides the best of both therapies without additional complexity or limitation. The two stage filter design achieves the superior urea clearance of post-dilution hemodiafiltration, while offering unsurpassed clearance of toxins in the middle-molecule range.


top of the page

Wrap Technology

The Autowraptec was formulated in 2002 to bring you the latest in wrapping technology and products. The first machine was conceived and market tested in 2002.  The first prototype is scheduled for completion during the fourth quarter of 2005. This client has developed several state-of-the-art products for the semiconductor, toy and medical industries. Always ground breaking leading to new trends in each industry.

With health consciousness at an all time high in the world, the restaurant industry will be the first to realize the benefits and needs of this type of equipment. To present silverware to the customer in the cleanest fashion, the restaurant industry has decided that wrapping the silverware in the napkin is the best way to achieve this today. Unfortunately, this is time consuming and still not hygienic enough for today's world, since the silverware is still being handled by hands several times during the process of sorting and wrapping. Its A Wrap was conceived to solve these problems and help restaurants keep their costs down.


top of the page

What Others Are Saying
Web site designed by Diztinct, Inc.